A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Copanlisib (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 13 Nov 2018 Planned End Date changed from 21 Oct 2020 to 1 Oct 2020.
- 13 Nov 2018 Planned primary completion date changed from 21 Oct 2019 to 1 Oct 2020.
- 13 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 1 Feb 2019.